2024.V1版NCCN指南更新：乳腺癌用药选择.docx

《2024.V1版NCCN指南更新：乳腺癌用药选择.docx》由会员分享，可在线阅读，更多相关《2024.V1版NCCN指南更新：乳腺癌用药选择.docx（18页珍藏版）》请在优知文库上搜索。

1、2024.V1版NCCN指南更新：乳腺癌用药选择2024年1月25日，乳腺癌NCCN指南更新至2024.V1版，此次药物治疗方面的更新主要涉及化疗药物的选择和剂量的调整，具体更新内容如下。并且本文汇总了最新版乳腺癌NCCN指南推荐的靶向、免疫药及方案选择，仅供参考。01、术前/辅助治疗方案HER2阴性的三阴性乳腺癌（TNBC）其他推荐方案调整：紫杉醇+卡钳（不同给药方式）调整为2A类证据多西他赛+卡钳删除“仅用于新辅助治疗”，调整为2A类证据National Comprehensive Cancer Network-NCCN Guidelines Version 1.2024 Invasive

2、 Breast Cancer PMierts in th OMnP0tfi dd MreCa ae petMrv. ttjt. them m no data On se9jenerg or 2 guide *lem ma EUde Mge IMIITNBC. The um ofvant PemeIIafneb (cBxy 2A E B BMOurirB.BINVLPREOPCRATivEzaojuvanttherapyregimens*TherglmnMtdMthetblIocHR2-ogvdMMrc(gory1(xcptwboiMkWd)whenudIn5djuvntMftlng.HEMqe

3、MxRgflkT911s: Dwe-dnseAC(doxorubclncycophophmWJfoilowdorpreMbypclHaxlvcy2vMfcb DM-tonMAC(doxorub*cirvcyclophophmldfottowdorprcMbyvrclypcMaxto TC(docUx4andCyclophosphamkJc) OUparib.if90mUn0BRCA12mutotk, HtghvitNTNBC:Prcprttv.PembfOliZUmbCMt)OPSgpclltxl,o4lwdbyproprtlvPeenbM以UfnM)cycloptophmMdr.andamr

4、cycHne4)MdCbOmOtXfa*:CapociUbIfWUm*jInCfttaCWCumtUnc: Dm-dnwACdoxorubcincyckphosphmtd) AC(doxofuMcifvcyclophcephamido)vry3WMkS(ctoghxphfnldwdRgimm:ACIollowodbydocoalvPacIHaxoICartlOPtotin(various*cduls)(category2A)D0CUx4CrtplMbn(CW90ry2A)AdditionalConsMeratfomforTMROCVingProoprativoAduvantThocapy(Bl

5、NY-LJ)ABamaMIaNBne乂docatml.PJeBM.rtfpadtod)toWteuhAedtxMMpMMntsduetomoSctauiyg.ryprvMym*ctt11IfWttliUedtofWwWordortMbomdpacMaieishouldtxtexceedi25ntn,niscoeptadletocftargethe1rmstationIeQXnCeIoWane(*GOr*xMKR24oetedteryIaBoWBdbyAC.cCOngrBS3ootadg11(Apart)torIyhxjvvtCtwmorMrap/.Or2)MdMldMMaftarprWvCfw

6、noihtapy M-poti.H三2wgatumor.if1)24osiMlyeprodtsaftercmcmray(cM90ry2A),ot2)eWUdMflrpropratkthmpyand dnc*lUge.ptfhoogcMgB.ER”&.Ftumorgcor*3AjatQuParc)CaIbeusd811cu5&WItIndomotcrawHER2阳性乳腺癌其他推荐方案调整:NCCNNational Comprehensive Cancr Network*新增紫杉醉/卡伯+曲妥珠单抗+帕妥珠单抗NCCNGuidelinesVersion1.2024InvasiveBreastCan

7、cerAMrnatM taaM gdoctawl pad*i burvirVbolrd adid mjr to Wtettuled tor Mted paUmk du to mxlcal nMt*y (to. rpwnf rMd) If SUtsttiied tor wm。PKIgH or dooaUul. thtn t wMly dose ( atjnrtt(xnd pacMaiel 6oUd not oMd 125 m0m1.ltB IccaptiblB to tfMrs c adrmtataon MQUeaCO to Uxano wh or MmUt HER2Urg4td torjy)

8、folowd by ACt PactUT . tBftuznat) my ba ooUMred tor patnt t kMMk T1 .N0.M0. HER2-poiK (teeMe. PefgJarV to*e not Cfegtlo tor Cthor Standvtf uwnt regmns due to comorbdOm.9Comat rwM)foovttfng adja MturunwoontaMng therapy fcr pMianU vt H R-pot. 02poO diMM Wflh a pod rtsk of reamnoe. E tent or tddta MSOd

9、alOd *5naratinbMn* who hvAng5 or ado4MAAfwb mtMr MrknOMnIt TraMiXimtf)In COmbett3 WG an artracydn * atsodod MttiAgnAcant cardtoc loxc COnCUnWrt um of tr*lu2ur1ab and pf1uzumM)wff an anrclno SbaJd B wdod.UPdad muRs from t) antAPHTY Mri in *R2os4s brt roor. wth a rn9an rotow-i f 84 yovt. hM COmrTned G

10、t gnft Cf add” pooptotifyrMt(umb) TCHP(doctaxVort)opitirtr*stuzumMprtusumab) IfnorldualdlsoasafWrproprMtvothrapyornoprprattvthrapy:CompiotouptoonyarofHER2tar9tdthrapywMtrastuzumab1(cM90ry1)tprtuzumab IfrduldMsCpropfttvtherapy:Ado4rMtuzumbntninIgory1)fonIfdotrxumbmtnkwdkcolinu*dfortoxteity.IMnIrMtuxu

11、mab(ctgocy1)1pgMg.trb(cWfloryifUWuIMCfUlnCkcumMfc: DocoUxoiCyclaphospIwnkSetrastuzumab ACfollowedTIrMtuzumabh(doxorbcincyc*opbopmMIoIIowmIbyPyplutrMtuamb.vhou38us) ACIollowodbyTbtrastuzumabpoclitax4trastuzumabPortUZUfnabh AdotrMtuzutnabmtantin(TDM-1)(duvlMttmgOrtfy)OtherRconwnnxlbtrastuzumab(doxorubclrVcyclophopamktofoHcwdbydocUxdtrMtuzumb)ACt/odbydoc*taxlbtrMummbXrtMZUrnt(donJbklnGeoph*p3nMfoowmlbydocCax4PcWU3QoMMuzumabprtuzumbAddHIo